Fulgent Genetics, Inc.
NASDAQ:FLGTMedical - Diagnostics & Research
+$0.33 today
- Market cap
- $702.11M
- Beta
- 0.92
- P/E (TTM)
- -7.5
- EPS (TTM)
- -$2.39
Volume 0.39M
Average 0.55M
FLGT Operating Margin
Operating income as a percentage of revenue, showing the profitability of core operations.
Fulgent Genetics, Inc.NASDAQ: FLGT
Operating Margin · Q1 FY2026 · quarter ended Mar 2026
Operating margin narrows to -48.7%
Operating margin was -48.7% in Q1 FY2026, down 21.7 pp from a year earlier. On a trailing-twelve-month basis it was -33.1%, down 8.5 pp year over year. Over 3 fiscal years it narrowed by 57.1 pp.
Context
- Operating margin widened in 1 of the last 3 fiscal years.
What to watch
Whether operating margin reaches the consensus estimate from 1 analysts of -15.5% for the fiscal year ending Dec 2026, up from -28.2% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -48.7%-5.2 pp QoQ
- Last fiscal yearDec 2025
- -28.2%-2.2 pp YoY
- LTMMar 2026
- -33.1%-8.5 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -21.7 pp | +10.6 pp | +32.3 pp |
| 1 year | -2.2 pp | +12.7 pp | +14.8 pp |
| 3 years | -57.1 pp | +20.5 pp | +77.6 pp |
| 5 years | — | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Operating Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -28.2%
- Year-over-year change
- -2.2pp
| Period | Period end | Operating Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -28.2% | -2.2pp |
| FY2024 | 2024-12-31 | -26.1% | +41.5pp |
| FY2023 | 2023-12-31 | -67.6% | -96.4pp |
| FY2022 | 2022-12-31 | 28.8% | -39.3pp |
| FY2021 | 2021-12-31 | 68.1% | — |
Operating Margin vs competitors
How FLGT compares with its peers on the latest reported figures
- FLGT's LTM Mar 2026 operating margin of -33.1% is the 5th highest of the 8 companies compared; the peer median is -13.3%.
- Its year-over-year change of -8.5 pp is the 5th highest of 8, against a peer median of +4.2 pp.
- Over three fiscal years its change of -57.1 pp compares with a peer median of +52.5 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
BLLNBillionToOne, Inc. | LTM Jun 2026 | 10.9% | +24.4 pp | — |
| LTM Jun 2026 | -8.6% | +8.1 pp | +21.8 pp | |
| LTM Jun 2026 | -10.7% | +4.2 pp | +52.5 pp | |
WGSGeneDx Holdings Corp. | LTM Jun 2026 | -13.3% | -14.8 pp | +281.7 pp |
| LTM Mar 2026 | -33.1% | -8.5 pp | -57.1 pp | |
| LTM Sep 2026 | -39.4% | +9.6 pp | +76.6 pp | |
| LTM Mar 2026 | -46.3% | -31.3 pp | +12.5 pp | |
| LTM Mar 2026 | -158.9% | -80.6 pp | — | |
FRNMFreenome, Inc. Common stock | — | — | — | — |
| Peer median (excluding FLGT) | -13.3% | +4.2 pp | +52.5 pp | |
Competitors are the stored peer set for FLGT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 992.58M | 618.97M | 289.21M | 283.47M | 322.67M |
| Cost of Revenue | 215.53M | 252.07M | 184.76M | 176.26M | 191.8M |
| Gross Profit | 777.05M | 366.9M | 104.46M | 107.22M | 130.88M |
| Gross Margin | 78.3% | 59.3% | 36.1% | 37.8% | 40.6% |
| Research & Development | 24.22M | 28.91M | 41.44M | 48.82M | 53.91M |
| Selling, General & Admin | 75.17M | 149.99M | 130.47M | 124.35M | 160.04M |
| Operating Expenses | 101.1M | 188.37M | 299.99M | 181.13M | 221.97M |
| Depreciation & Amortization | 11M | 32.66M | 26.14M | 24.93M | 24.12M |
| EBITDA | 692.04M | 217.7M | (147.45M) | (26.86M) | (45.83M) |
| EBITDA Margin | 69.7% | 35.2% | -51.0% | -9.5% | -14.2% |
| Operating Income | 675.95M | 178.53M | (195.53M) | (73.92M) | (91.1M) |
| Operating Margin | 68.1% | 28.8% | -67.6% | -26.1% | -28.2% |
| Interest Income | 1.35M | 5.62M | 21.61M | 31.3M | 30.92M |
| Interest Expense | 0 | 1.01M | 488K | 170K | 75K |
| Other Income / Expenses | 5.08M | 5.5M | 21.44M | 21.96M | 21.07M |
| Income Before Tax | 681.03M | 184.03M | (174.09M) | (51.96M) | (70.03M) |
| Pre-Tax Margin | 68.6% | 29.7% | -60.2% | -18.3% | -21.7% |
| Income Tax Expense | 174.8M | 42.1M | 1.15M | (8.14M) | (8.39M) |
| Net Income | 507.36M | 143.4M | (167.83M) | (42.71M) | (60.51M) |
| Net Margin | 51.1% | 23.2% | -58.0% | -15.1% | -18.8% |
| EPS (Basic) | 17.13 | 4.76 | (5.63) | (1.41) | (1.97) |
| EPS (Diluted) | 16.26 | 4.63 | (5.63) | (1.41) | (1.97) |
| Weighted Avg Shares | 29.41M | 30.1M | 29.78M | 30.24M | 30.78M |
| Weighted Avg Shares (Diluted) | 30.98M | 30.96M | 29.78M | 30.24M | 30.78M |
Fulgent Genetics, Inc.
NASDAQ:FLGT
Intrinsic Alpha fair value
Locked
Current Price
$25.13
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.